Shilpa Ltd. has evolved into a knowledge driven, R&D focused company aspiring to bring advanced, effective treatments at an affordable cost. With the overarching goal of providing affordable health and quality of life, our scientists are constantly trying to break new grounds in the development of medicines in cost effective manner thus passing on the price benefit to our clients and ultimately to patients. We are committed towards developing innovative technologies and creating a knowledge base in chemical synthesis, high quality generic formulation and development of new drug delivery systems.
Shilpa Medicare aims to be amongst the leaders within the generics industry, setting new industry standards through constant innovation. With our 3 development centers situated in different locations, we are working on a dynamic pipeline of molecules where we believe early opportunities and further scope of improvement is there, following the loss of valid patent protection. Our expertise and know-how in the development and production of generic products, ranges across a variety of technologies from APIs, injectable, solid orals, small peptides, novel drug delivery systems in relation to diversified therapeutic areas: oncology and anti-retroviral therapies being the primary focus.
We continue to look for new opportunities to work with other organizations: private sector or from academics, as well as licensing or acquisition firms. We understand and value the potential and exceptional results these partnerships can bring. Besides in-house R&D efforts, we also undertake innovation of new products as per customers' requirement for both APIs and Finished Dosage Forms.